- 1. Table of Contents (Page 1)
- 2. Basic Information (Page 2)
- 3. Packaging & Pictures (Page 3-8)
- 4. European Test & Technical Documentation Review Report (Page 9-13)
- 5. Registration on DIMDI & Declaration of Conformity (Page 14-15)
- 6. ISO Production Standards Report (Page 16-23)
- 7. Manufacturer Qualification Certificate & Export License (Page 24-28)

Disposable Medical Face Mask Inherent-Type I

Brand: Inherent

Type No.: YX001

Performance standard: EN 14683:2019 + AC:2019(E) Annex B

/C/D & YY/T 0969-

2013, tested by TÜV Rheiland, Intertek & GTTC

Production standards: ISO 10933-10:2010 & ISO 10993-

5:2009, tested by CCIC

Classifications: Type I (Non-Sterile), No latex ingredients

Material: Two-layer PP Nonwoven fabric and One-

layer BFE95 Meltblown fabric (3 layers)

Mask specifications: Universal, 17,50 x 9,50 cm

Earloop design: Breathable and comfortable for prolonged w

earing

Date of manufacture: From July 2020

Expiration date: 2 years

Packing specifications: 10 pcs. / PE bag, 50 pcs. /

box, 40 boxes 2000 pcs. / carton, 16 cartons / euro pallet

Carton measurements: 51.5 x 39 x 35.5 cm, G.W. 9.1 KGS.

Stock available in Rotterdam The Netherlands and Frankfurt am Main Germany























Prüfbericht-Nr.: Test Report No.: Auftrags-Nr. 168264746 Seite 1 von 12 Page 1 of 12 Auftragsdatum: May 13, 2020 Order date: Order date:
Hunan EEXI Technology & Service Co., Ltd.
No.6, North of Pinglou road, Lluyang Hi-leich industrial development zone, Hunan, China Auftraggeber: Prüfgegenstand: Test item: EN 14683:2019+AC:2019 except for clause 5.2.6 Prüfgrundlage: Test specification: Wareneingangsdatum: May 14, 2020 Date of receipt: 20200504 May 14, 2020 to May 28, 2020 Prüfzeitraum: Testing period: See Attachment: Photo documentation for details. Ort der Prüfung: Prüflaboratorium: TÜV Rhe
Testing laboratory: Co., Ltd.

Prüfergebnis*: Pass TÜV Rheinland (Shenzhen) Co., Ltd.

A TÜVRheinland®

60373876 001

Produkte Products

Condition of the fast item at delivery.

2 s before 2 s and 2 s before 3 s be Dieser Prüfbericht bezieht sich nur auf das o.g. Prüfmuster und darf ohne Genehmigung der Prüfstelle nich zusungsweise verviellätligt werden. Dieser Bericht berechtigt nicht zur Verwendung eines Prüfzeichens. his test report ony relates to fee a. m. test sample. Wöhou germaiscon of the set center this test report an of permitte duplicated in extracts. This test report does not entitle to carry any test mark.

TÜV Rheinland (Shenzhen) Co., Ltd., East of F/1, F/2 - F/4, Building 1, Cytrio Technology Building, No. 6 Langshan No. 2 Road, North Hi-tech Industry Park, Nanshan District, Shenzhen, P.R. China

▲ TÜVRheinland® Page 2 of 12 Report No. 60373876 001 EN 14683:2019+AC: 2019 Medical face masks — Requirements and test methods:: 60373876 001 Total number of pages: TÜV Rheinland (Shenzhen) Co., Ltd.

1 FE ast 8.2 «F. Cybo Technology Building No.1. No.16 Kejibei 2nd Rod. (High-Technology Building No.1. No.16 Kejibei 2nd Rod. (High-Technology A Shenzhen, China Haman District, 518057. Shenzhen, China Eki Technology & Service Co., Ltd.

Address No.6, North of Pionini and Service Co., Ltd. No.6, North of Pingtou road, Liuyang Hi-tech industrial development zone, Hunan, China Test specification:

Standard ... EN 14883 2019+AC 2019

Test procedure ... Type test

Non-standard test method NA

Test Report Form No. ... EN 14883 2019+AC 2019_A

Test Report Form Originator ... TÜV Rh (SZ)
 Master TRF
 2020-03

 Test Item description
 Disposable Medical Face Mask
 Trade Mark..... Inherent

▲ TÜVRheinland® Page 3 of 12 Report No. 60373876 001 List of Attachments (including a total number of pages in each attachment): tation (6 pages) Summary of resung:
Tests performed (name of test and test clause):
Tests performed (name of test and test clause):
Tests performed (name of test and test clause):
TUV Rheinland (Sternzhen) Co., Ltd.

1 FE.sat S. 2.4E. Cybio Technology Building No.1,
No.16 Keigliei 2nd Road, High-Tech Inductrial Pairk
North Namshand Daint, S. 18905, Shenzhien, China Clause 5.2.2 Bacterial filtration efficiency (BFE) Sichuan Testing Center of Medical Devices No. 4-28, Xinye Road, High tech west Area Chengdu, Sichuan, 611731, P.R.China

TÜVRheinland® Page 4 of 12 Report No. 60373876 001 Copy of marking plate The artwork below may be only a draft. The use of certification marks on a product must be authorized by the respective NCBs that own these marks. Instruction

Code of preparation of the names, April 1, 1922

Product name: Disposable medical face mask
Type and Specification: Filt actions, 17.5-9 Scm

Product name: Disposable medical face mask
Type and Specification: Filt actions, 17.5-9 Scm

Passar risk of the Instructions before use Type and Expecification Filt actions, 17.5-9 Scm

Production Recens Rec. Human reducing Administration permissions 2020/0023

Registration No. Human reducing Administration permissions 2020/0023

Registration No. Human reducing device registration permissions 2020/0023

Registration No. Human reducing device registration permissions 2020/0023

Registration No. Human reducing device registration permissions 2020/0023

Registration No. Human reducing device produced devices produce on-busines, and infections porticulally in equilibration of purplies insulations. The medical lisco make in single-sea, disposable device, provider non-tainle, and interfaced to be used for partiest and other parents to reduce the first dynamic of infections. Structures and Components.

Structures and Components.

The make is made by their mask, rouge piece and our loops. The Mann mask is made to the make the mask is made to the make the mask of the mask in made to the mask in made to the mask of the mask of the mask in made to the mask of the mask of the mask in made to the mask of the mask is made to the mask of the ma Back code refer to package
Use by date refer to package
Address Effectives 60, 2003 Hamburg Germany
Address Effective 60, 2003 Hamburg Germany
Address Effetive 60, 2003 Hamburg Germany

QMF-RT-33008SHG Revision number: 1.0 Effective date: 2020-03-12

Testing	
Date of receipt of test item(s)	0
Dates of tests performed	
Possible test case verdicts:	See cover page
- test case does not apply to the test object	N/A
- test object does meet the requirement	
- test object was not evaluated for the requirement	
- test object does not meet the requirement	
The tests results presented in this report relate only it This report shall not be reproduced except in full with List of test equipment must be kept on file and availal Additional test data and/or information provided in the	out the written approval of the testing laboratory. ble for review. a attachments to this report.
The tests results presented in this report relate only to This report shall not be reproduced except in full with List of test equipment must be kept on file and available.	the object tested. out the written approval of the testing laboratory. Die for roview, attachments to this report, seed as the decimal separator.
The tests results presented in this report relate only \$\frac{1}{1}\$ this report shall not be reproduced except in full with List of test equipment must be kept on file and availadditional test data and/or information provided in the Throughout this report a \(\subseteq \text{comma} to \subseteq \text{point} \) comma \$I \(\subseteq point is supported to the comma of the point is supported to the comma of the	the object tested. out the written approval of the testing laboratory. Die for roview, attachments to this report, seed as the decimal separator.

RT-33088HG Revision number: 1.0 Effective date: 2020-03-12


Effective date: 2020-03-12

Revision number: 1.

Effective date: 2020-03-12

EN 14683:2019+AC:2019						
Clause	Requirement + Test	Result - Remark	Verdict			
	For thick and rigid masks such as rigid duckbill or cup masks the test method may not be suitable as a proper seal cannot be maintained in the cascade impactor. In these cases, another valid equivalent method shall be used to determine the BFE.	Not such mask.	N/A			
	When a mask consists of two or more areas with different characteristics or different layer-composition, each panel or area shall be tested individually.	Same characteristics and same layer-composition declared by manufacturer.	N/A			
	The lowest performing panel or area shall determine the BFE value of the complete mask	See above	N/A			
5.2.3	Breathability		P			
	When tested in accordance with Annex C, the differential pressure of the medical face mask shall conform to the value given for the relevant type in Table 1.	See appended table 5.2.3	Р			
	If the use of a respiratory protective device as face mask is required in an operating theatre and/or other medical settings, it might not fulfill the performance requirements with regard to differential pressure as defined in this European Standard. In such case, the device should fulfill the requirement as specified in the relevant Personal Protective Equipment (PPE) standard(s).		N/A			
5.2.4	Splash resistance		N/A			
	When tested in accordance with ISO 22609:2004 the resistance of the medical face mask to penetration of splashes of liquid shall conform to the minimum value given for Type IIR in Table 1.	See appended table 5.2.4 Type I mask.	N/A			
5.2.5	Microbial cleanliness (Bioburden)		Р			
	When tested according to EN ISO 11737-1:2018 the bioburden of the medical mask shall be ≤ 30 CFU/g tested (see Table 1).	See appended table 5.2.5	Р			
5.2.6	Biocompatibility		N/E			
	According to the definition and classification in EN ISO 10993-1:2009, a medical face mask is a surface device with limited contact.	The biocompatibility is not evaluated in this test report.	N/E			
	The manufacturer shall complete the evaluation of the medical face mask according to EN ISO 10993-1:2009 and determine the applicable toxicology testing regime.		N/E			
	The results of testing should be documented according to the applicable parts of the EN ISO 10993 series.		N/E			
	The test results shall be available upon request.		N/E			
6	Marking, labelling and packaging		Р			

QMF-RT-3908SHG Revision number: 1.0 Effective date: 2020-03



		EN 1468	3:2019+AC:2019		
Clause	Require	ment + Test	R	esult - Remark	Verdict
5.2.3		TABLE: Breathability (Differen	tial pressure)		P
Batch/ lot no.:	Test Specimen number- Test area number	(Pa/cm²)	The averaged differential pressure for each test specimen (Pa/cm²)	Flow rate (l/min)	Remarks
20200 504	1-1	15.5		8.0	-
504	1-2	22.4		8.0	
	1-3	26.9	22.5	8.0	-
	1-4	23.9		8.0	
	1-5	23.7		8.0	
	2-1	16.3	23.6	8.0	-
	2-2	23.4		8.0	
	2-3	28.3		8.0	
	2-4	23.7		8.0	-
	2-5	26.3		8.0	-
	3-1	13.7		8.0	-
	3-2	23.7		8.0	
	3-3	24.7	21.0	8.0	-
	3-4	21.7		8.0	-
	3-5	21.4		8.0	-
	4-1	14.8		8.0	-
	4-2	23.1		8.0	
	4-3	24.1	22.1	8.0	
	4-4	25.7	1 [8.0	-
	4-5	22.9		8.0	-
	5-1	20.0		8.0	
	5-2	23.4		8.0	
	5-3	21.3	22.4	8.0	
	5-4	24.6		8.0	-
	5-5	22.8	1	8.0	-



5.2.5	TABLE: M	icrobial cleanliness (Bio	oburden)		P
Batch/ le	ot no.:	Mask(under test) no.:	Weight of each mask (g)	Total bioburden per individual mask (CFU/g)	Remarks
20200504		1	3.0	<1	
		2	2.9	<1	-
		3	2.9	<1	-
		4	2.9	<1	-
		5	3.0	<1	


End of EN 14683 test report


DMF-RT-33008SHG Revision number: 1.0 Effective date: 2020-03-


















intertek TEST REPORT





Summary of testing:	
With reference to following standard:	
 EN 14683:2019+AC:2019 Medical face masks – Requirements and test methods Type I 	



Intertek Testing Services Shenzhen Ltd. Guangzhou Branch 深圳天祥质量技术服务有限公司广州分公司

161. E201. E301. E401. E501. E601. E701. E601 Tet: +86 20 8213 9001 Fax: +86 20 8208 9909 Postcode: 510663

Page 3 Of 6

intertek TEST REPORT





Bacterial Filtration Efficiency (BFE)
 As Per EN 14683:2019+AC:2019 Medical face masks – Requirements And Test Methods Annex B.

Test Item	Results (%)					Performance Requirement for
	Specimen (1)	Specimen (2)	Specimen (3)	Specimen (4)	Specimen (5)	Medical Face Mask (%)
Bacterial Filtration Efficiency (BFE)	99.5	99.6	99.8	99.7	99.6	Type I: ≥95

Remark: This Item Is Not Under The Testing Scope Of CNAS Accreditation.

This test item was conducted in Caipin Road, Guangzhou Science City, GETDD, Guangzhou, Guangdong.

intertek

TEST REPORT





Test Item	Result (cfu/g)					Limit
	Specimen (1)	Specimen (2)	Specimen (3)	Specimen (4)	Specimen (5)	(cfu/g)
Microbial cleanliness	1	<1#	<1#	<1#	<1#	Type I: ≤30

Remark: This Test Item Was Conducted In Caipin Road, Guangzhou Science City, GETDD, Guangzhou, Guangdong.

101. E201. E301. E401. E501. E601. E701. E801 Tet: +86.20.8213.9001 Fax: +86.20.8208.9909 Postcode: 510883

intertek

TEST REPORT

Tests Conducted (As Requested By The Applicant)



End of Report

101. E201. E301. E401. E501. E501. E701. E801 Tet +86 20 8213 9001 Fax +86 20 8208 9999 Pestcode: 510863

P13



Allgemeine Anzeigepflicht nach §§ 25 und 30 Abs. 2 MPG neral Obligation to Notify pursuant to §§ 25 and 30 (2) Medical Devices Act, MPG

Formblatt für Medizinprodukte, außer In-vitro-Diagnostika

uständige Behörde / Competent authority	
Code DE/CA05	
Bezeichnung / Name Behörde für Gesundheit und Verbraucherschutz,	Referat V43
Staat / State Deutschland	Land / Federal state Hamburg
Ort / City Hamburg	Postleitzahl / Postal code 20539
Straße, Haus-Nr. / Street, house no. Billstraße 80	
Telefon / Phone +49-40-428280	Telefax / Fax +49-40-427310017
E-Mail / E-mail medizinprodukte@bgv.hamburg.de	
nzeige / Notification	
Registrierdatum bei der zuständigen Behörde Registration date at competent authority 09.04.2020	Registriernummer / Registration number DE/CA05/MP-238321-2556-00
Typ der Anzeige / Notification type	
S Erstanzeige / Initial notification	
£ Änderungsanzeige / Notification of change	
£ Widerrufsanzeige / Notification of withdrawal	
Frühere Registriernummer bei Änderungs- und Wide Previous registration number if notification has been	
Anzeigender nach § 25 MPG / Reporter pursuant to	§ 25 Medical Devices Act, MPG
£ Hersteller / Manufacturer	
S Bevollmächtigter / Authorised Representative	
£ Einführer / Importer	
£ Verantwortlicher für das Zusammensetzen von Sy	stemen oder Behandlungseinheiten nach § 10 Abs. 1 und
MPG \ Assembler of systems or procedure packs put	rsuant to § 10 (1) and (2) Medical Devices Act, MPG
£ Betrieb oder Einrichtung (aufbereiten) nach § 25 A	Abs. 1 MPG i. V. m. § 4 Abs. 2 MPBetreibV
Institution (processing) pursuant to § 25 (1) Medic	cal Devices Act, MPG in connection with § 4 (2) MPBetreib
£ Betrieb oder Einrichtung (sterilisieren) nach § 25 A	Abs. 2 i. V. m. § 10 Abs. 3 MPG
Institution (sterilizing) pursuant to § 25 (2) in conn	ection with § 10 (3) Medical Devices Act, MPG

-1-

	Exu § 4 Abs. 1 Nr. 1 CHAD Formularmanware 00001
Anzeigender / Reporting organisation (per	son)
Code DE/0000040627	
Bezeichnung / Name Shanghai International Holding Corpo	ration GmbH (Europe)
Staat / State Deutschland	Land / Federal state Hamburg
Ort / City Hamburg	Postleitzahl / Postal code 20537
Straße, Haus-Nr. / Street, house no. Eiffestrasse 80	
Telefon / Phone +49-40-2513175	Telefax / Fax +49-40-255726
E-Mail / E-mail shholding@hotmail.com	
Hersteller / Manufacturer	
Bezeichnung / Name Hunan EEXI Technology&Service Co.,	
Staat / State CN	Lu.
Ort / City Liuyang	Postleitzahl / Postal code 410323
Straße, Haus-Nr. / Street, house no. No.6, North of Pingtou road, Liuyang I	Hi-tech Industrial Development Zone,
Telefon / Phone +86-731-83371666	Telefax / Fax
E-Mail / E-mail overseas01@idore.com.cn	
Sicherheitsbeauftragter für Medizinprodul Safety officer for medical devices pursuar	cte nach § 30 Abs. 2 MPG 9)
Bezeichnung / Name Llang Jin	n to 3 or (2) medical borious Act; in to
Staat / State Deutschland	Land / Federal state Hamburg
Ort / City Hamburg	Postleitzahl / Postal code 20537
Straße, Haus-Nr. / Street, house no. Eiffestr.80	
Telefon / Phone +49-40-2513175	Telefax / Fax +49-40-255726
E-Mail / E-mail	

.2.

		Antige 1 (au § 4 Abs. 1 Nr. 1 DINDIV) Formularmarmer 00381588
١	ertreter / Deputy (optional)	
	Bezeichnung / Name	
	Telefon / Phone	Telefax / Fax
	E-Mail / E-mail	
	£ Erstanzeige / Initial notification S Änderungsanzeige / Notification of change	

-3-

DIMOI

Analysis (Application of Control of Control

Servicelinks

• Wegsselser

• Anistang for Anal

Anlage 1 (zu § 4 Abs. 1 Nr. 1 DIMOR/)

£ Semikri	tische Medizinprodukte / Semicriti	cal medical devices	
£ Grup	pe A / Group A		
2 Grup	pe B / Group B		
£ Kritisch	e Medizinprodukte / Critical medic	al devices	
£ Grup	pe A / Group A		
£ Grup	pe B / Group B		
£ Grup	pe C / Group C		
Numme	er der Bescheinigung / Certificate	number	
Sterilisatio	nsverfahren / Sterilisation procedu	ures	
£ Dampfs	terilisation / Steam sterilisation		
£ Gasster	ilisation / Gas sterilisation		
£ Strahler	nsterilisation / Radiation sterilisation	on	
£ andere	/ others		
Angew	andtes Verfahren / Applied proced	lure	
versichere, d	lass die Angaben nach bestern Winformation given above is correct	issen und Gewissen gemach to the best of my knowledge	t wurden.
t	Hamburg	Datum Date	2020-04-07

Arriage 1 (zu § 4 Abs. 1 Nr. 1 DRADN)

Hamburg Datur 2028-04-07

Name Liang Jin

Unterschift
Signature

Bearbeitungsvermerke / Processing notes
Nur von der zustlandigen Behörde auszufüllen / To be filled in only by the competent authority

Bearbeitur / Pernon responsible

Frau Sylvia Frenzel

040 42237-2120

-5-



CONTENTS

Page 2 of 11

In this study, we took guinea pigs to observe the skin sensitization of the test article according to

Study Verification and Signature 1.0 Purpose....

10.0 Results of the test... 11.0 Conclusion.....

12.0 Record..... 13.0 Confidentiality Agr





Skin Sensitization Test

Guinea Pig Maximization

Final Report

Article Name: Disposable medical face mask Report Number: CSTBB20030201 Method Standard: ISO 10993-10: 2010

CCIC Huatongwei international inspection (Suzhou) Co., Ltd

Hunan EEXI Technology&Service Co.,Ltd.

CCIC Huatongwei international inspection (Suzhou) Co., Ltd J, Building G, Ruoshui Read 388, Suzhou, Jiangsa, China, 512123 Tel: 0512-876572881 Page I of 11

Report No.: CSTBB20030201

Notices

- Please apply for rechecking within 15 days of receiving the report if there is any objection.
 Any erasure or without special testing seal renders the report null and void.
 The report is only valid when signed by the persons who edited, checked and approved it.

- The report is only responsible for the test results of the tested samples.
 The report shall not be reproduced except in full without the written approval of the company

Page 3 of 11

Page 4 of 11

Date Completed

Study Verification and Signature



Protocol Number SST2003006603BB Technical Initiation Date 2020-03-20 Technical Completion Date 2020-04-17 Final Report Completion Date 2020-04-18

Page 5 of 11

1.0 Purpose

.D Purpose

The test was designed to evaluate the potential of a test article to cause skin sensitization. The test is used as a rocedure for scenering of contact allergens in guinea pigs and extrapolating the results to humans, but it does not stabilish the actual risk of sensitization.

地

Biological evaluation of medical devices Part 10: Tests for irritation and skin sensitization (ISO 10993-10:

Biological evaluation of medical devices-Part 12: Sample preparation and reference materials (ISO 10993-12:2012) Biological evaluation of medical devices-Part 2: Animal welfare requirements (ISO 10993-2:2006)

3.0 Test and control articles

Groups	Test article	Negative Control Article(Polar)	Negative Control Article(Non-Polar)	Positive Control
Name	Disposable medical face mask	Sodium Chloride Injection (SC)	Sesame Oil (SO)	2, 4-Dinitrochlorobenzeno (DNCB)
Manufacture	Hunan EEXI Technology&Service Co.,Ltd.	Shijiazhuang No.4 Pharmaceutical	Jiangxi xinsen natural vegetable oil co., Ltd.	TOKYO CHEMICAL INDUSTRY CO., LTD
Sterilization state	No	1	1.	1
Size	17.5cm*9.5cm	500 ml	25 kg	25 g
Model	YX001	1	1.	1
Lot Batch#	Not provided	1912121907	181120	H2UKD-DM
Test Article Material	PP non-woven, Meltblown filtration layer, earloop and nose clip	/	'	,
Physical State	Solid	Liquid	Liquid	Solid
Color	Not provided	Colorless	Light yellow	Light yellow
Package material	PE poly bag and paper box	1	ž.	1
Concentration	1	0.9 %	,	Induction Concentration: 0.5 % Challenge Concentration: 1.0 % Dissolved in ethanol
Total	Not provided	1	1	1

Page 6 of 11

Report No.: CSTBB20030201

Surface/Weight				
Storage Condition	Room Tep.	Room Tep.	Room Tep.	Room Tep.

4.0 Identification of test system

4.1 Test animal

Species: Hartley Guinea Pig (Cavia Porcellus) Number: 30 (20 Test +10 Control)

Initial body weight: 301.5~313.5 g

usly used in other experimental procedures

Health status: Healthy, not prev Animal identification: Ear tag

Cages: Plastic cage
Acclimation Period: 7 days under the same conditions as for the actual test

Acclimation Period: 7 days under the same commons as no me and a second and the common of the common

5.0 Animal Management

Animal purchase: Wuxi hengtai experimental animal breeding co. LTD SCXK (SU) 2015-0004

Redding: Cornocob Jiangsu Xictiong Pharmaceutical Bio-engineering Co., Ltd.
Feed: Guinea pigs were fed with full-price pellets Jiangsu Xietong Pharmaceutical Bic
Water: Drinking water met the Standards for Drinking Water Quality GB 5749-2006 eutical Bio-engineering Co., Ltd.

water: Drinking water met the Standards for Drinking Water Quanty Gis 5 Animal room temperatures [18-26] C. Animal room relative humidity, 30 %-70 % Lights: 12 hours light/dark cycle, full-spectrum lighting Personnel: Associates involved were appropriately qualified and trained Selection: Only healthy, previously unused animals were selected

There were no known contaminants present in the feed, water, or bedding expected to interfere with the test

6.0 Equipment and reagents

6.1 Instrum

Constant Temperature Vibrator (SHB007, calibration data: 2020/3/16), Autoclave (SHB026, calibration data: 020/3/16), Electronic scale (SHB017, calibration data: 2020/3/16)

Freund's adjuvant Complete liquid (SIGMA, Lot No: SLBR3877V), Sodium dodecyl sulfate (SDS SIGMA,

Page 7 of 11

Report No.: CSTBB20030201

7.0 Experiment design

The extracts of test article will be prepared according to the following steps:

Aseptic Sampling			Extraction in sterile vessels					
Sampling Manner	Actually sampling	Ratio	Re	eagent	Temperature	Time	pH	
11/1-1-	570.2 cm ²	6cm ² : 1 ml	SC	95.0 ml	50 °C	72 h	5.5	
Whole	570.2 cm ²	ocm: 1 mi	SO	95.0 ml	30 C	/2 ft	5.5	

Whole \$70.2 cm² cent²: Ital \$0, \$9.0 ml \$0.0 × 12.0 × 12.0 \$5.5 Beth inducements and excitations were prepared by the number of times. The state of the leaching solution did not change visually after the leaching was advanced. After extraction, the samples were stored at room temperature for no more than 24 h. The extraction solution is clear, and the pH value has not been adjusted, filtered, centrifuged,

for as more than 24 h. The cutraction solution is clear, and the plf value has not been adjusted, filtered, centrifuged, diluted and other processes. The control solution was prepared under the same conditions.


7.2 Test method.

7.2.1 transformal induction phase!

A pair of 0.1 mil strateformal injections was made for each of the following, into each animal, at the injection sites (A. B and C) as shown in Figure 1 in the clipped intracepular region.

Site A. A 507 of columne ratio shallow emulsion of Fround's complete adjuvant mixed with the closen solvent.

Site D. The test sample (undiluted extract); the control animals were injected with the solvent about of Fround's complete adjuvant and the solvent (50 %); the control animals were injected with an emulsion of the blank liquid with adjuvant.



The maximum concentration that can be achieved in Intradermal induction phase I did not produce irritation,

The maximum concentration that can be achieved in Intradermal Induction phase I did not produce irration, animals are pretensive with 10% sould modesy affato 24(2) power before the topical induction application.

Art 7 d after completion of the intradermal induction phase, administer test article extract by topical application to the intrascapolar region of each animal, using a pack of area approximately 8 cm² (absorbent gazze), so as to cover the intradermal injection sites. Secure the patches with an occlasive dressing. Remove the dressings and patches after (4882) h.

Treat the control animals similarly, using the blank liquid alone.

7.2.3 Challenge phase

Page 8 of 11

Report No.: CSTBB2003201
At 14d after completion of the topical induction phase, challenge all test and control animals with the test
sample. Absorbent gazzes (2.5 cm2.5 cm) were soaked respectively with test article and control article. Apply the
test article extract and control article topically to two sites that were not treated during the induction stage. Secure
with an occlaised extensing. Remove the dressings and patches after (24s2) h.

8.0 The results observed

8.0 The results observed
The day after challenge exposure, the patch will be removed and the area cleaned gently with gauze if necessary. The site will be wiped gently with a 10.9% saline assisted gauze sponge prior to each scoring period. The challenge sites will be observed for signs of irritation and sensitization reaction, as indicated by crythema and edema. If necessary, the fur will be durved or clipped in advance for the convenience of dermal score.

Daily challenge observation scores will be recorded approximately 24, and 48 hours after patch removal in accordance with the following classification system for skin reactions:

Table 1 Magnusson and Kligman scale

Patch test reaction	Grading scale
No visible change	0
Discrete or patchy crythema	1
Moderate and confluent crythema	2
Intense erythema and/or swelling	3

9.0 Evaluation criteria

9.0 Evaluation criteria
Magnasson and Kligman grades of 1 or greater in the test group generally indicate sensitization, provided grades of less than 1 are seen in control animals.

If grades of 1 or greater are noted in control animals, then the reactions of test animals which exceed the most severe reaction in control animals are presumed to be due to sensitization.

If the response is equivocal, rechallenge is recommended to confirm the results from the first challenge.

The outcome of the test is presented as the frequency of positive challenge results in test and control animals.

Possible of the test is presented as the frequency of positive challenge results in test and control animals.

All animals were survived and no abnormal signs were observed during the study. Individual results of dermal scoring for the challenge appear in Table 2.

Scoring for the crainering appear in 1800 &.

11.0 Conclusion

The test article showed no evidence of causing delayed dermal contact sensitization in the guinea pig. Results and conclusions apply only to the test article tested. Any extrapolation of these data to other articles is the sponsor's

13.0 Confidentiality Agreement

Report No.: CSTBB20030201

Table 2 Guinea pig Sensitization Dermal Reactions

G	iroup	No.	Pretest weigh(g)	Finished weigh(g)		enge patch ed 24h later	The Challe was remove		Positive
			weigh(g)	weign(g)	Erythema	Swelling	Erythema	Swelling	rate
		1	312.8	350.1	0	0	0	0	
		2	2 310.8 3 311.7	349.8	0	0	0	0	
			311.7	346.8	0	0	0	0	
	Test	4	311.8	346.5	0	0	0	0	
		5	313.5	350.2	0	0	0	0	0%
		6	308.2	349.3	0	0	0	0	026
		7	310.3	352.1	0	0	0	0	
SC			350.6	0	0	0	0		
		9	307.9	346.8	0	0	0	0	
		10	311.9	347.9	0	0	0	0	
		11	306.8	346.4	0	0	0	0	
	Control	12	311.6	351.3	0	0	0	0	
		13	307.1	347.9	0	0	0	0	-
		14	311.5	356.1	0	0	0	0	
		15	305.9	349.3	0	0	0	0	
		16	301.5	346.6	0	0	0	0	
		17	311.9	351.6	0	0	0	0	
		18	307.3	348.6	0	0	0	0	
		19	306.0	344.4	0	0	0	0	
	Test	20	302.2	340.5	0	0	0	0	0%
	lest	21	307.3	348.1	0	0	0	0	0%
		22	301.9	344.9	0	0	0	0	
SO		23	306.8	346.1	0	0	0	0	
		24	312.0	356.1	0	0	0	0	
		25	307.3	348.3	0	0	0	0	
		26	312.3	355.7	0	0	0	0	
		27	311.6	354.5	0	0	0	0	
	Control	28	309.8	354.0	0	0	0	0	-
		29	306.3	347.9	0	0	0	0	
		30	307.4	345.9	0	0	0	0	

Page 10 of 11

Report No.: CSTBB20030201

			Table 3	Positive	control			
Group No.	No.	Pretest	Finished			The Chall was rem	Positive	
	100000	weigh(g)	weigh(g)	Erythem	Swelling	Erythem	Swelling	rate
	1	311.2	351.7	2	0	2	0	
	2	315.6	360.2	1	0	1	0]
	3	317.2	352.7	0	0	1	0	
	4	312.8	353.9	1.	0	1	0	100%
Test	5	306.9	341.1	2	0	2	0	
lest	6	312.2	350.6	0	0	1	0	
	7	317.1	352.2	1	0	2	0	
	8	306.8	350.0	1	0	1	0	
	9	316.5	348.7	1	0	2	0	1
	10	317.6	350.2	2	0	2	0	1
	11	320.5	364.5	0	0	.0	0	
	12	307.6	350.2	0	0	0	0	
Control	13	306.9	345.1	0	0	0	0	-
	14	310.0	352.3	0	0	0	0	1
	15	315.8	346.6	0	0	0	0	1

Note: The positive control was CSTBB20010001P1(Finish date: 2020-02-07).









Skin Irritation Test Extraction Method

Final Report

Article Name: Disposable medical face mask Report Number: CSTBB20030203

Method Standard: ISO 10993-10: 2010

Test Facility

Hunan EEXI Technology&Service

CCIC Huatongwei international inspection (Suzhou) Co., Ltd

No.6 north of Pingtou road, Liuyang Hi-tech industrial development zone, Hunan, China

Room 101, Building G, Rueshui Roud 388, Suzhou, Jiangsu, China

Page 11 of 11

CONTENTS

otices	3
bstract	4
udy Verification and Signature	5
1.0 Purpose	6
2.0 Reference	6
3.0 Test and control articles	
4.0 Identification of test system.	6
5.0 Animal Managment	
6.0 Equipment and reagents	7
7.0 Experiment design	7
8.0 The results observed	
9.0 Evaluation criteria.	9
10.0 Results of the test	9
11.0 Conclusion.	9
120 Record	9
13.0 Confidentiality Agreement	9

Page 2 of 11

Abstract

In this study, we took New Zealand white Rabbits to observe the skin irritation of the test article according to ISO10993-10:2010.

The test article were extracted in Constant Temperature Vibrator at 50 °C, 60 rpm for 72 h by 0.9 % Sodium Chloride Injection and Sesame Oil, Apply 0.5 ml extracts of test article or control to 2.5 cm×2.5 cm absorbent gauze patches, and then apply the patch soaked with the extract of test article or control directly to the skin on each side of each rabbin, and then ways the application sites with a bandage for a minimum of 4 h. At the end of the contact time, remove the dressing. The describe and score the skin reaction for crythema and ocdema for each application site at each time interval. Record the appearance of each application site at (± 0.1) h, (24 ± 2) h, (48 ± 2) h and (72 ± 2) h following removal of the patches.

The results showed that the rabbits in the negative control group (0.9 % Sodium Chloride Injection, Sesame Oil) retained a normal appearance throughout the test and showed no skin irritants. A severe skin reactions for crythema and oedema were shown in the positive control group (SDS). While in test article group, the response of skin on testing side did not exceed that on the control side. The skin reactions for crythema and oedema were not observed in test article group. The data of each group met the acceptance criteria, and the results of this test were considered valid.

Based on the above results, it can be concluded that under the experimental conditions, the test article Disposable medical face mask has no potential skin irritation on rabbit in the extraction Report No.: CSTBB20030203

Notices

- 1. Please apply for rechecking within 15 days of receiving the report if there is any objection.
 2. Any crasure or without special testing seal renders the report null and void.
 3. The report is only valid when signed by the persons who edited, checked and approved it.
 4. The report is only responsible for the star earlies of the tested samples.
 5. The report shall not be reproduced except in full without the written approval of the company.

Page 3 of 11

Report No: CSTBB20030203

Study Verification and Signature



Protocol Number
Protocol Effective Date SST2003006601BB Technical Initiation Date 2020-03-20 2020-03-27 Technical Completion Date 2020-04-18

Date Completed

Page 5 of 11

Report No.: CSTBB20030203

1.0 Purpose
To evaluate the potential skin irritation caused by test article contact with the skin surface of rabbits and extrapolating the results to humans, but it does not establish the actual risk of irritation.

2.0 Reference

Biological evaluation of medical devices Part 10: Tests for irritation and skin sensitization (ISO 10993-10:

Biological evaluation of medical devices-Part 12: Sample preparation and reference materials (ISO 10993-12:2012)

Biological evaluation of medical devices-Part 2: Animal welfare requirements (ISO 10993-2:2006)

3.0 Test and control articles

Groups	Test article	Negative Control Article(Polar)	Negative Control Article(Non-Polar)	Positive Control
Name	Disposable medical face mask	Sesame Oil (SO		10 % sodium dodecy sulfate (SDS)
Manufacture	Hunan EEXI Technology&Service Co.,Ltd.	Shijiazhuang No.4 Pharmaceutical	Jiangxi xinsen natural vegetable oil co., Ltd.	SIGMA
Sterilization state	No	1	1	1
Size	17.5cm*9.5cm	500 ml	25 kg	25 g
Model	YX001	1	1	/
Lot Batch#	Not provided	1912121907	181120	SLBL2304V
Test Article Material	PP non-woven, Meltblown filtration layer, earloop and nose clip	,	- 1	7
Physical State	Solid	Liquid	Liquid	Solid
Color	Not provided	Colorless	Light yellow	Colorless
Package material	PE poly bag and paper box	/	1	1
Concentration	-1	0.9%	£	10 %
Total Surface/Weight	Not provided	/	į.	7
Storage Condition	Room Tep.	Room Tep.	Room Tep.	Room Tep.


4.0 Identification of test system

Species: New Zealand white Rabbit

Report No.: CSTBB20030203

Use the rabbits with healthy intact skin. Fur was generally clipped within 24 b period before testing on the backs of the rabbits, a sufficient distance on both sides of the spine for application and observation of all test sites (approximately 10-15 cm).

Apply 0.5 ml extract (i) of test article or control to 2.5 cm².2.5 cm absorbent gauze patches, and then apply the patch soaked with the extract of test article or control directly to the skin on each side of each rabbit as shown in Figure 1, and then wrap the application sites with a bundage (semi-exclusive or occlusive) for a minimum of 4h. At the end of the contact time, remove the dressing.



1- Cranial end, 2- Test site, 3- Control site, 4- Clipped dorsal region, 5- Caudal end Figure Location of skin application sites

8.0 The results observed

The Describe and acore the skin reaction for erythema and oedema according to the scoring system given in Table 1 for each application size at each time interval. Record the appearance of each application size at (±0.1) h, (242) h, (4812) h and (72.82) h following removal of the patient.

Table 1 Classification System for Skin Reaction

Erythema and Eschar Formation:	Numerical Grading
No erythema	0
Very slight erythema (barely perceptible)	1
Well-defined erythema	2
Moderate erythema	3
Severe erythema (beet redness) to eschar formation preventing grading of erythema	4
Edema Formation:	
No edema	0
Very slight edema (barely perceptible)	1
Well-defined edema (edges of area well-defined by definite raising)	2
Moderate edema (raised approximately 1mm)	3
Severe edema (raised more than 1mm and extending beyond exposure area)	4
Maximal possible score for irritation	8
Irritation Response Categories in the Rabbit	

Page 8 of 11

Report No.: CSTBB20030203

Report No.: CSTBRO0030201

Number: 6

Sec. 3 § 3, 3 d

Weight: 2.69-2.17 kg

Health status: Bealthy, not previously used in other experimental procedures

Animal identification: Ear status

Cages: Similes seed cage

Accimation Proist. 7 days under the same conditions as for the actual test

42.2 untification of red saystem

The rabbit is specified as an appropriate animal model for evaluating potential skin initiants by the c urrent testing standards. Positive central 10% sodium dosbeeyl sulface has been substantiated at HTW with this method.

50.4 Animal Managment

Animal purchase West length experimental animal breeding on LTD SCXX (SU) 2015-0004

Animal purchase: Wuxi hengtai experimental animal breeding co. LTD SCXK (SU) 2015-0004

Animal purchase: Waxi lengtais experimental animal breeding oo. LTD SCXX (SU) 2015-0004
Bodding: //
Feed: Experimental rabbits were fied a maintenance diet, Woxt hengtai experimental animal breeding oo. LTD
Water: Drinking water met the Standards for Drinking Water Quality GB 5749-2006
Animal room temperature: 18-28 °C.
Animal room temperature: 18-28 °C.
Animal room reduce humsdiy: 30-970 %
Lights: 12 hours lights ocycle, full expectural lighting.
Personnel: Associates involved were appropriately qualified and trained
Selection: Only bodding, pervisoraly unsoral animals were selected.
There were no known contaminants present in the feed, water, or bedding expected to interfere with the test.

6.0 Equipment and reagents

De Ediphysion and vogene
 All Instruments
 Constant Temperature Vibrator (SHB007, calibration data: 2020/3/16), Autoclave (SHB026, calibration data: 2020/3/16), Electronic scale (SHB017, calibration data: 2020/3/16)

2000/31/6), Electronic scale (STEDUT), CHIPTERING Made According to the following steps:

7.1 Sample preparation

The extracts of test article will be prepared according to the following steps:

Aseptic Sampling			Extraction in sterile vessels					
Sampling Manner	Actually	Ratio	Re	agent	Temperature	Time	pH	
Whole	570.2 cm ²		SC	95.0 ml	40.00	22.1	5.5	
Whole	570.2 cm ²	6cm2: 1 ml	SO	95.0 ml	50 °C	72 h	5.5	

1932 or 1942 1930 55.00 190°C 12b 55.

The state of the descrips addission distort ochange visually are the leading was subsect. The cutset of the descrips against old not change visually after the leading was a subsect. The extractions were clear, and the pH value has not been adjusted, filtered, centrifuged, diluted and other processes, before dosing stored at room temperature no more than 24 h. The control solution was prepared under the same conditions 7.2 For method

Response Category	Mean score
Negligible	0 to 0.4
Slight	0.5 to 1.9
Moderate	2 to 4.9
Severe	5 to 8
9.0 Evaluation criteria	
Use only (24±2) h, (48±2) h and (72±2) h observations for calcu	ilation.
After the 72 h grading, all erythema grades plus oedema grades	s (24±2) h, (48±2) h and (72±2) h were totalle
separately for each test article and blank for each animal. The prima	ry irritation score for an animal was calculate
by dividing the sum of all the scores by 6 (two test/observation sites,	three time points).
by dividing the sum of all the scores by 6 (two test/observation sites, To obtain the primary irritation index for the test article, add al	
To obtain the primary irritation index for the test article, add al	
To obtain the primary irritation index for the test article, add al	Il the primary irritation scores of the individua
To obtain the primary irritation index for the test article, add al animals and divide by the number of animals. When blank or negative control was used, calculate the prima	Il the primary irritation scores of the individu- ry irritation score for the controls and subtra-
To obtain the primary irritation index for the test article, add al animals and divide by the number of animals. When blank or negative control was used, calculate the primar that score from the score using the test material to obtain the primary	Il the primary irritation scores of the individu- ry irritation score for the controls and subtra-
animals and divide by the number of animals.	Il the primary irritation scores of the individu ry irritation score for the controls and subtra irritation score.

animals and divide by the number of animals.

When blank or negative control was used, calculate the primary irritation score for the controls and subtract that score from the score using the test material to obtain the primary irritation score.

10.0 Results of the test

All animals were survived and no abnormal signs were observed during the study. According to what observed, the response of shin on testing side did not exceed that on the control side. Thus, the primary irritation index for the test article was calculated to be 0. See table 2.

S THE

The test result showed that the response of the test article extract was categorized as negligible under the test

12.0 Record

All raw data pertaining to this study and a copy of the final report are retained in designated Huatongwei 13.0 Confidentiality Agreement

Statements of confidentiality were as agreed upon prior to study initiation.

Page 9 of 11

	Rabbit	Pretest	Finished	Group	Reaction	Inter	val (hours):	score-left	right				
Reagent	No	No weigh(g)	weigh(g)	Group	Reaction	1h	24h	48h	72h				
	1 2.10			Test	Erythema	0/0	0/0	0/0	0/0				
		2.18	Article	Oedema	0/0	0/0	0/0	0:0					
	- 1	2.10	2.18	Negative	Erythema	0/0	0/0	0/0	0:0				
				Control	Oedema	0/0	0/0	0/0	0:0				
SC 2 2.09		Test	Erythema	0/0	0/0	0/0	0:0						
	2	2.00	2.16	Article	Oedema	0/0	0/0	0/0	0:0				
SC	4	2.09	2.16	Negative	Erythema	0/0	0/0	0/0	0:0				
				Control	Oedema	0/0	0/0	0/0	0:0				
		10		Test	Erythema	0/0	0/0	0/0	0:0				
	3	2.17	2.24	Article	Oedema	0/0	0/0	0/0	0:0				
	3	2.17		Negative Control	Erythema	0/0	0/0	0/0	0:0				
					Oedema	0/0	0/0	0/0	0:0				
		Primary in	ritation index				(
			2.14	Test	Erythema	0/0	0/0	0/0	0/0				
	4	2.04		2.14	2.14	2.14	2.14	Article	Oedema	0/0	0/0	0/0	0/0
	*	2.04						2.14	Negative	Erythema	0/0	0/0	0/0
				Control	Oedema	0/0	0/0	0/0	0:0				
				Test	Erythema	0/0	0/0	0/0	0.0				
so	5	2.11	2.20	Article	Oedema	0/0	0/0	0/0	0/0				
50	3	2.11	2.20	Negative	Erythema	0/0	0/0	0/0	0:0				
				Control	Oedema	0/0	0/0	0/0	0:0				
				Test	Erythema	0/0	0/0	0/0	0:0				
	6	2.13	2.21	Article	Oedema	0/0	0/0	0/0	0:0				
		2.13	12.4	Negative	Erythema	0/0	0/0	0/0	0:0				
		Control		Oedema	0/0	0/0	0/0	0:0					

Report No.: CSTBB20030203

Rabbit No	Group	Reaction	Interva	d (hours): see	we-left site/r	ight site
Rappit No	Group	Reaction	1h	24h	48h	721
	Name and American	Erythema	0.40	1/2	2/3	3/3
1	Positive control	Oedema	0/0	2/1	2/2	3/3
	No. of the last of	Erythema	0.40	0.0	0.0	0.40
	Negative Control	Oedema	0./0	0/0	0.0	0./0
	Positive control	Erythema	0/1	2/1	3/3	4/3
2	Positive control	Oedema	1/0	2/2	3/3	3/4
2		Erythema	0.40	0/0	0.0	0/0
	Negative Control	Oedema	0.40	0.0	0.0	0./0
		Erythema	1/0	1/2	3/3	4/3
196	Positive control	Oedema	0/1	2/1	3/4	3/4
3		Erythema	0/0	0/0	0.0	0/0
	Negative Control	Oedema	0./0	0/0	0.0	0/0

Page 10 of 11









In Vitro Cytotoxicity Test

MTT Method

Final Report

Article Name: Disposable medical face m Report Number: CSTBB20030204

Method Standard: ISO 10993-5: 2009

Hunan EEXI Technology&Service Co.,Ltd.

CCIC Huatongwei international inspection (Suzhou) Co., Ltd
Address Room 101, Building G, Rusoliui Road 388, Suzhau, Liangsu, China, 512123 Tel: 0512-87657288 Fax: 0512-87657288
Päge 1 of 9

CONTENTS Notices
Abstract

1.0 Purpose.
2 0 Reference.
3.0 Test and control articles.
4 0 Identification and justification of test system.
5 0 Equipment and reagents.
6.0 Experiment design and dose.
7.0 Statistical method.
8 0 Evaluation criteria.
9 0 Results of the test.
11 0 Conclusion.
11 0 Record.

Page 2 of 9

Report No.: CSTBB20030204

6 しも

神

Notices

- 1. Please apply for rechecking within 15 days of receiving the report if there is any objection.

- Learness apply for feederscange within 15 sups or feeding the group of the desired projection.
 2. Any exastive or whitton special testing seal renders the report null and void.
 3. The report is only valid when signed by the persons who edited, checked and approved it.
 4. The report is only responsible for the test results of the tested samples.
 5. The report shall not be reproduced except in full without the written approval of the company.



Page 3 of 9

Report No.: CSTBB20030204 Study Verification and Signature Protocol Effective Date 2020-03-23 Technical Initiation Date 2020-03-23 2020-03-25 Technical Completion Date Final Report Completion Date 2020-04-18 Joneson She Date Completed

Abstract

In this study, mammalian L-929 cells were cultured in vitro according to ISO 10993-5:2009 to test the potential cytotoxicity of the test article.

The test articles and the control material were separately placed in MEM medium containing 10% fetal bovine serum, and extracted in a 37 °C incubator for 24 hours. After the end of the extraction, the cell culture medium in the 96-well plate (10* cells/well) cultured for 24 hours was removed and replaced with the corresponding extract, cultured in 3° C, 5% CO₃, 59% CO₃, 59% Co do to 2.4 hours. After the culture, the morphology and cell lysis of the cells were observed under the microscope, and the cytotoxicity of the test samples was determined by MTT assay.

density polyethylene) were well-formed throughout the experiment and showed no cytotoxic reaction. A severe cytotoxic response was shown in the positive control group (ZDEC). The 100% concentration of the test extract retained a normal appearance after 24 hours of incubation, and the cell viability was 78.1%. The data of each group met the acceptance criteria, and the results of this test were valid.

Based on the above results, it can be concluded that under the experimental conditions, the test article Disposable medical face mask have no potential toxicity to L-929 in the MTT method.

1.0 Purpose The purpose of the test is to determine the potential cytotoxicity toxicity of a mammalian cell culture (mouse fibroblast L-929 cells) in response to the test article.

Biological evaluation of medical devices-Part 5: Tests for In Vitro Cytotoxicity (ISO 10993-51 2009) Biological evaluation of medical devices-Part 12: Sample preparation and reference materials (ISO 10993-12:

Groups	Test article	Negative Control Article	Positive Control Article	Blank Control
Name	Disposable medical face mask	High Density Polyethylene Film	ZDEC	MEM medium, with addition 10% FBS
Manufacture	Hunan EEXI Technology&Service Co.,Ltd.	Hatano Research Institute. FDSC	Sigma-Aldrich.	Hyclone
Size	17.5cm*9.5cm	3 cm×10 cm (5 sheets)	25 g	500 ml
Model	YX001	1	7	1
Lot Batch#	Not provided	C-161	BCBQ6847V	AE29441978
Test Article Material	PP non-woven, Meltblown filtration layer, earloop and nose clip	-1-	1	T
Physical State	Solid	Solid	Solid	Liquid
Color	Not provided	White	White	Pink
Packaging Material	PE poly bag and paper box	1	./	7.
Sterilized or Not	No	No	No	Yes
Concentration	1	1	0.1%	7
Total Surface	Not provided	1	7	7
Storage Condition	Room Tep.	Room Tep.	Room Tep.	4°C

Note: The information about the lext article was supplied by the sponsor wherever applicable.

4.0 Identification and justification of text system
L+92 mouse fibroblast cells obtained from American Type Culture Collection (ATCC).
L+929 cells have been used for cytotocicity atudies because they demonstrate sensitivity to extractable cytotocic articles. Also, the test article is extracted and administered in vitro to mouse fibroblast L929 cells through a solvent companible with the test system, which is the optimal route of administration available in this test system as recommended in ISO 10993-5.

Page 6 of 9

5.1 Instruments.
Vertical pressure steam sterillzer (SHB026), CO; Incubator (SHB002), Seed Straight Scale (SHB076), Electronic Ballance (SHB016), Clean bench (SHB014), Multislans Spectrum Microplate Spectrophotometer (SHB002), Bench type low speed centrifuge (SHB022), Inverted microscope (SHB005)

MEM (Hyclone, AE2944)978), FBS (Clark, JC65116), Penicillin-Streptomycin (Gibco, 2145453), Trypsi n (Gibco, 2048080), PBS (Hyclone, AE29451445), MTT (3-44,5-Dimethylthiazol-2-yl)-2,5-diphenyletrazolium bromide) (Sigma, MKBG2038V), Isopropyl alcoho (Marklin, C10394867)

notimize (signal, MENULAUSEX), INSPIRITY SECTION (MENULAUM, (1039-801))

6.1 Sample preparation
According to the table below, asspic extraction of the test article sealed and incubated in MEM medium (10%, FRS) at 77 C, 55 CO and 60 mm for 24 hours.

Groups	Sampling Actually Manner sampling		Sampling Sterilizati Aseptic Extraction In Inert Contains on					Final Extract
Groups			Method	Ratio	Extracts	Condition	pН	Clear or Not
Test article	Whole	570.2 cm ²	EO	6 cm ² : 1 ml	95.0 ml	37 ℃ 24 h	7.4	Clear
Negative Control	Random	60 cm ²	UV	3 cm ² : 1 ml	20.0 ml	37 °C 24 h	7.4	Clear
Positive Control	Random	0.02 g	Filter	0.1 g: 100 ml	20.0 ml	37 ℃ 24 h	7.4	Clear
Blank Control	7	¥	1	1	10.0 ml	37 °C 24 h	7.4	Clear

Control 10.0 ml 27 °C. Clear

The changes of the leaching solution was observed after extraction. No particulates or color changes were observed in per- and post-extraction, and immediately be used in the follow-up experiment. The color and pH of the extraction solution did not change before and after use, and the pH value was 7.4 after leaching.

6.2 Test method

Acresi method in the continuous process and many continuous many of the management of the CP Test method.

Acresi procedures were used for handling cell cultures. L-929 cells were cultured in MiSM medium (10%, SE, 159. Pencilistilla-Streptomycin solution) at 37° C in a handlinded atmosphere of 5% CO, then digested by 0.25% tryption containing EDTA to get single cell suspension. 1×10° cellowin suspension were obtained by centrifuging (100° pm., 5min and re-dispersing in MEM medium).

The suspension cells were dispensed at 100 µf or well in 96-well plats, and cultured in cell incubator (5% CO, 37° C, >90%), beautisty, Cell morphology was centuated to verify that the mentodaye was satisfactory.

After the cells grew to about 79% and form a monolayer, original culture medium was discarded. The 96-well plates were then metad with 100 µf of extract of test article (10%), 75%, 50%, 25%), control article, segative article and positive raticle respectively. The 96-well plate was incubated at 37° C in cell incubator of 55% CO, for 24 h. Six replicates of each test were tested.

Page 7 of 9

Report No.: CSTBB20030204

	cell lysis and slight growth inhibition.
	The cells showed a round shape and a change
25% Test article	in cell morphology occasionally, and there
extract	were particles in the cytoplasm, occasionally
	cell lysis and slight growth inhibition.

9.2 Results of the cell vitality

Table2 Results of the cell vitality

Group				OD	value				T. 1
Group	1	2	2 3	4	5	6	X	s	Viab. (%)
Blank control	0.601	0.663	0.638	0.655	0.606	0.629	0.632	0.025	100.0
Negative control	0.598	0.582	0.598	0.599	0.597	0.593	0.595	0.006	94.1
Positive control	0.054	0.062	0.061	0.059	0.068	0.064	0.061	0.005	9.7
100% test article extract	0.489	0.497	0.486	0.495	0.492	0.502	0.494	0.006	78.1
75% test article extract	0.523	0.525	0.535	0.524	0.519	0.508	0.522	0.009	82.6
50% test article extract	0.539	0.538	0.547	0.536	0.535	0.537	0.539	0.004	85.2
25% test article extract	0.549	0.555	0.567	0.589	0.585	0.565	0.568	0.016	89.9

Under the conditions of this study, the test article have no potential toxicity to L-929 cells.

11.0 Record

All raw data pertaining to this study and a copy of the final report are to be stored in the designated archive s at Hustongwei.

files at Huatongwei. 12.0 Confidentiality Agreement

Statements of confidentiality were as agreed upon prior to study initiation.

Page 9 of 9

Report No. CSTBB20030204
After incubation, observe the cell morphology first and then discard the culture medium. Add 50 µ MTI
(Imgrill) to each well and then incubated at 37 °C in a himstified atmosphere of 5% (Co) for 2 hours. The liquid in each well was tipped out and 100 µ I sopropyl alcolo was added to each well to suspend the cell layer.

Evaluate the suspension above with a dual-wavelength spectrophotometer with the measurement wavelength at 570 mm.

7.0 Statistical method

Meanistandard deviation (\bar{x} ±a)

The cell cytotoxicity ratio = OD₂₉₀ of test (or positive or negative) article group OD₂₉₀ of blank control

8.0 Evaluation criteria

- 8.0 Evaluation criteria

 8.1 The 50% extract of the test article should have at least the same or a higher viability than the 100% extract.
 Otherwise the test should be repeated.

 8.2 The lower the Vah 5's value, the higher the cytotoxic potential of the test article is.

 8.3 The lower the Vah 5's value, the higher the cytotoxic potential.

 8.4 The Vah 5's of the 100% extract of the test article is the final result.

 9.0 Results of the test

 9.1 Results of the cell morphology

 Table 1 Observation of the cell morphology

11

Group	Before inoculation	Before treated with extract	24 h after treatment		
Blank control	A 1		Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth.		
Negative control			Discrete intracytoplasmatic granules, no lysis, no reduction of cell growth.		
Positive control			Nearly complete or complete destruction of the cell layers.		
100% Test article extract	Discrete intracytoplasmatic granules, no cell lysis, no reduction	Discrete intracytoplasmatic granules, no cell lysis, no reduction	The cells showed a round shape and a change in cell morphology occasionally, and there were particles in the cytoplasm, occasionally cell lysis and slight growth inhibition.		
75% Test article extract	of cell growth.	of cell growth.	The cells showed a round shape and a change in cell morphology occasionally, and there were particles in the cytoplasm, occasionally cell lysis and slight growth inhibition.		
50% Test article extract			The cells showed a round shape and a change in cell morphology occasionally, and there were particles in the cytoplasm, occasionally		





中华人民共和国医疗器械注册证

注册证编号:湘械注准20202140297

注册人名称	湖南一喜科技服务有限公司
注册人住所	湖南浏阳高新技术产业开发区坪头北路6号3栋
生产地址	湖南浏阳高新技术产业开发区坪头北路6号3栋
代理人名称	不适用
代理人住所	不适用
产品名称	一次性使用医用口罩(非无菌型)
型号、规格	产品按照面罩形状分为平面形(PM),按照佩戴方式可以分为耳挂式 (G)、绑带式(B)或头带(D)式,按照尺寸可以分为A、B、C、D. E、F、G-七种规格。
结构及组成	本产品由菜布、募夹、口罩带组成、菜布内外层由无纺布, 中间层由 焙喷布制成, 口罩带由非织造布或栓紧带制成, 募夹由可弯折的聚内 烯鼻夹材料制成。该产品非无菌供应。
适用范围	适用于佩戴者在无在体液和喷溅风险的普通医疗环境下的卫生护 理。
附件	产品技术要求
其他内容	
备 注	1. 该产品为应急审批注册,有效期为八个月,2. 该产品在延续/变更》 册时应按医疗器械注册管理要求完善相关资料。

审批部门: 湖南省药品监督管理局

















证书号: USA20E40925R0M

兹证明

湖南一喜科技服务有限公司

统一社会信用代码: 91430181MA4PHUE510

注册地址:湖南浏阳高新技术产业开发区坪头北路6号 生产地址:湖南浏阳高新技术产业开发区坪头北路6号3栋一、二楼 办公地址:湖南浏阳高新技术产业开发区坪头北路6号办公楼

环境管理体系符合标准 ISO 14001:2015

环境管理体系适用范围

一次性使用医用口罩(非无菌型)、一次性使用医用口罩(无菌型)、医用外科口罩 (非无菌型)、医用外科口罩(无菌型)的生产(该公司许可证范围内) 及其所涉及场所的相关环境管理活动

初次发证日期 2020年04月20日 证书颁发日期 2020年04月20日 证书统发日期 2020年05月12日 证书统发日期 2020年05月12日





北京在有規構





证中心有限公司



HUNAN EEXI TECHNOLOGY & SERVICE CO., LTD. Unified Social Credit Code: 91430181MA4PHUE510

Registered/Office Address: No.6 North of Pingtou Road, Liuyang Hi-Tech Industrial Development Zone, Hunan, China

Production Address: Floor 1 and 2, Building 3, No.6 North of Pingtou Road, Liuyang Hi-Tech
Industrial Development Zone, Hunan, China

Has been audited to conform to the following Environmental Management System standard

ISO 14001:2015

TISO 14001:2015

This Environmental Management System is valid for the
The production of disposable medical masks (non-sterile), disposable medical masks (sterile), medical surgical masks (non-sterile) and medical surgical masks (sterile) (within the company's license scope) and related environmental management activities of involved sites

Date of initial issuance: Apr. 20, 2020 Date of issumce: Apr. 20, 2020 Date of renewal: May. 12, 2020 Date of expiry: Apr. 19, 2023

Issued by: We Forgne

EACC















Test Report



VERIFICATION VERSITE: YVV. gttc. net. ca VERIFICATION COME. CSID-3465-54

APPLICANT: HANN EXIT FORMOLOGYASSEVICE CO., LTD. 会社を使う。 場所・当社理を予算会・ 出版では、場所・当社理を予算会・ 出版では、これでは、これでは、日本のようには、日本のよりには、日本のよりに

INFORMATION CONFIRMED BY APPLICANT 客户认定信息:
Disposable medical face mask一次往使用医用口取
Type产品型号: YX001, YX100
Classification等級: Type I

STANDARD ADOPTED 检验依据:

SEED "T When the standord's requirement "F Fell to most the standord's requirement """ No come SEED CONTROL OF THE SEED OF THE SEED CONTROL OF TH

Zishan Guo

Guangzhau Inspection Testing and Certification Group Co., Ltd.
Add: No.1, Zhajiang Read, Paryu Dietrict, Guangebou, Guangdong, P.R.China.

ZiShan Guo SENIOR ENGINEER





Test Report

(Electronic version)

No: 20R000976



Guangzhou Inspection Testing and Certification Group Co., Ltd. Add: No.1, Zhujiang Road, Panya District, Guangzhou, Guangdong, P.R. China.





Test Report (Rlectronic version)

Bacterial filtration efficiency (BFE) 细菌过滤效率 (BFE) Test method: EN 14683: 2019+AC: 2019 Annex B 製式方法; EN 14683:2019+AC:2019 別录B

Tet optipment:

斯波克克

斯波克克

Includes

Electronic blance

化子芹

Antickur

In Jan (April 1998)

广检集团 —GTTC—

口用面面过速效率(NFD)实验系统
The environmental conditions of the laboratory and test conditions:
安施整度等选择的数据数据的。
Total hosterian O CPU plate
耐雨危影。 O FU plate
耐雨危影。 O FU plate
用面的影响。 O FU plate
和证明的影响。 O FU plate
和证明的影响。



Guangzhou Inspection Testing and Certification Group Co., Ltd. Add: No.1, Zhujiang Road, Penys District, Guargehou, Guangdong, P.R. China.





Test Report

(Electronic version)

No: 20R000976

广检集团



Test Report

No: 20R000976

Sample 样品	T 计数之和	BFE 细菌过滤效率 (%)	Requirement 技术要求 (%)	Classification 級別	Conclusion 单项结论
1	13	99.31			
2	22	98.84			
3	22	98.84	≥95	Type I	Pass 符合
4	15	99.21	EN 14683:2019+AC:2019		65.10
5	18	99.05			
For each test specim 对于每个试样。按	以下公式以百分比用	erial filtration efficier 3式计算细菌过滤效	ncy B, as a percentage, using 車:	the following fo	rmula:
For each test specim 对于每个试样。按 B = (C - T) / C × 10 where 式中 B is bacterial filtrati B — 细葉过滤效率 C is positive control	以下公式以百分比用 0 on efficiency (BFE), 。为: average;	3式计算细菌过滤效		the following fo	emula:
对于每个试样,按 B = (C - T)/C × 10 where 式中 B is bacterial filtrati B — 细葉过滤效率 C is positive control C — 創性质控平均	以下公式以百分比用 0 on efficiency (BFE), 。为: average;	5式计算细菌过滤效 %。		the following fe	emula:







Test Report

(Electronic version)

No: 20R000976

Besults 测试结果.

Sample 样品	Bacteria 细菌 (CFU/g)	Fungi 真菌 (CFU/g)	Microbial cleanliness 洁净度-微生物 (CFU/g)	Requirement 技术要求 (CFU/g)	Classification 級別	Conclusion 单項结论
1	3	5	- 8	1		
2	5	3	8	≤30		14000
3	2	- 4	. 6	EN 14683:2019+AC:2019	Type I	Pass 符合
4	1	0	- 1		CONT. NO. 17.0	14.11
5	4	3	7	1		



Guangzhou Inspection Testing and Certification Group Co., Ltd.
Add: No.1, Zhujiang Rosé, Penyu Dioteix, Guangzhou, Guangdong, P.R. China.

Guangehou Inspection Testing and Certification Group Co., Ltd.
Add: No.1, Zhajing Road, Pasya District, Guangehou, Guangelong, P.R. China.





Test Report

(Electronic version)

No: 20R000976

Microbial cleanliness 清净度-微生物 Test method: EN ISO 11737-1:2018, Membrane filtration 獨武方法: EN ISO 11737-1:2018 模过滤法

現代方法: EN ISO 11777-12018 模式接法
Test principles.

Rid Sag.

Rid

Test equipment: 測试设备: Constant temperature incubator



Guangzhou Inspection Testing and Certification Group Co.,Ltd.
Add: No.1, Ztujiang Road, Panyu Disrict, Guangzhou, Guanghou, P.R.China.

Tul: +86-20-61994598 61994599





Test Report

(Electronic version)

No: 20R000976

Sample 样品	Differential pressure 压力差 (Pa/cm²)	Requirement 技术要求 (Pa/cm ²)	Classification 級别	Conclusion 单项结论
1	24.5			
2	27.1	<40		-
3	23.3	EN 14683:2019+AC:2019	Type I	Pass 符合
4	25.1			शन
5	27.3			





Test Report

(Electronic version)

No: 20R000976

Differential pressure 压力差 Test method: EN 14683:2019+AC:2019 Annex C 對試方法: EN 14683:2019+AC:2019 附录C

Test principle: 報式**建設**. 報式**建設**. 新式**建設**. 新式**设**. 新式**的**. 新式**以**. 新式**以**.

Test equipment: 獨试被备: GTTC-YLC-I Apparatus for differential pressure GTTC-YLC-I口原压力差测试仪

The environmental conditions of the laboratory and test condition: 实验室环境条件和测试条件:

dition each specimen for a minimum of 4 h by exposure to a temperature of (21±5) °C and a relative Protestament: Condition each specimen for a minimum of 4 h by exposure to a temperatu-humidity of (85.5)%. 預处理方式。温度(21.±5)℃、粗砂湿度(85.±5) 环境中预处理大产估 General Location of the areas of the mask the differential measurements specimen center 口观点力分别状化 展 记录中



Guangzhou Inspection Testing and Certification Group Co., Ltd.
Add: No.1, Zhujiang Road, Panyu District, Guangzhou, Guangdong, P.R.China.



——本报告结束(End of Report)——

Guangzhou Inspection Testing and Certification Group Co.,Ltd.
Add: No.1, Zhujiang Road, Patyu District, Guangzhou, Guangdong, P.R.China.